With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

Sarcoidosis is a rare systemic disease that afflicts an estimated 200,000 people in the U.S., more often people who are Black ...

Additionally, the company has initiated a new brepocitinib trial for cutaneous sarcoidosis, marking its third indication for the drug. Gline emphasized the strength of Roivant’s pipeline ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Tyr Pharma Inc (ATYR) reports robust financial health and significant progress in its pivotal phase three study for pulmonary ...

Cardiac sarcoidosis (CS) was a complication in about 10% of pulmonary sarcoidosis (PS) cases, investigators reported in Respiratory Medicine. The retrospective study assessed the prevalence, incidence ...

The following is a summary of "Respiratory abnormalities in sarcoidosis: physiopathology and early diagnosis using ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology ...

SAN DIEGO - aTyr Pharma, Inc. (NASDAQ: ATYR) reported a narrower-than-expected fourth quarter loss on Wednesday, but shares fell 4.8% in after-hours trading as investors focused on the company’s cash ...